Navigation Links
Menicon Undertakes With the Novovision Clinic a Paediatric Myopia Control Clinical Trial
Date:6/23/2008

NAGOYA, Japan, June 23 /PRNewswire/ -- Although previous studies suggest that orthokeratology contact lens wear slows the axial length growth of the eye in children with progressing myopia, some limitations in the methodology employed have been evident. Using a rigorous study design and precise optical measuring instruments, Menicon Co., Ltd. and the Novovision Clinic in Madrid are undertaking the Myopia Control with Orthokeratology contact lenses in Spain (MCOS) study to compare the axial length growth between white European myopic children wearing orthokeratology contact lenses (OK) and distance single-vision spectacles (SP) over a 2-year period. In this prospective, single-centre clinical trial, sixty-two subjects 6 to 12 years of age, and with myopia of -0.75 to -4.00 D and astigmatism < =1.00 D were randomly allocated wear OK or SP correction. Measurements of axial length (using partial coherence interferometry, Zeiss IOLMaster), anterior chamber depth, corneal topography, cycloplegic refraction and visual acuity are being performed at 6-month intervals. To date, no subjects have withdrawn from the study, no adverse events were evident and no contact lens fitting modifications were required in the OK group. The MCOS study offers a number of notable features: a prospective design; well matched samples and high resolution ocular biometry measures, which collectively should elucidate whether OK contact lens wear is a feasible method of myopia control.

"The MCOS study aims, using a rigorous study design and precise optical measuring instruments, at elucidating whether orthokeratology lens wear slows the axial length growth of the eye in children with progressing myopia. This study is of special relevance taking into account that the prevalence of myopia has increased substantially over recent decades and now is approaching 10-25% and 60-80% in industrialized societies of the West and East, respectively," commented Dr. Jacinto Santodomingo, Global Professional Relations Manager for Menicon Co., Ltd.

"We have been fitting orthokeratology lenses in our clinic for several years, during which we observed that myopia tended to progress less in children wearing orthokeratology lenses compared to children wearing other modalities of visual correction. We are delighted to participate in this unique clinical trial, which should prove whether we are correct about our preliminary observations," added Mr. Cesar Villa, Director of Optometry at Novovision.

About Menicon:

Menicon Co., Ltd. (http://www.menicon.com), founded by Mr. Kyoichi Tanaka in 1951, is Japan's first and largest contact lens manufacturer, and now is represented in over 30 countries. Menicon is a manufacturer dedicated to all areas of soft and GP contact lens related businesses including material development, lens designing, and manufacturing of contact lenses and care solutions. Menicon is a world-leader in the development of hyper-Dk GP (Menicon Z) and soft contact lenses (Menicon PremiO).

Contact:

Toshio Matsushima

Global Business Operations

Menicon Co., Ltd.

Phone: +81-52-937-5021

Fax: +81-52-935-1121

E-mail: matsushima@menicon-net.co.jp

URL: http://www.menicon.com


'/>"/>
SOURCE Menicon Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytels Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting
2. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
3. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
4. FDA Lifts Clinical Hold on Gentas Tesetaxel, a Leading Oral Taxane
5. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
6. iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials
9. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
10. Randomized Controlled Clinical Trial Shows Derma Sciences MEDIHONEY(TM) Eradicates MRSA From Chronic Venous Ulcers
11. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... , June 12, 2017 Kineta, Inc., a biotechnology ... Kineta Vice President of R&D and Head of ... Pandemic Preparedness for the Northwest and Beyond meeting ... on June 14, 2017 from 8:30-10:30 AM PDT at the ... Dr. Bedard will be joined by other ...
(Date:6/9/2017)... and INDIANAPOLIS , June 9, ... living with diabetes. In a further effort to help ... affected by this condition, the International Diabetes Federation (IDF) ... ) have come together for the second phase of ... Systems programme (BRIDGES 2), reaffirming their commitment to helping ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
Breaking Medicine Technology:
(Date:6/22/2017)... ... 2017 , ... Vighter, a premier provider of Unconventional Medical ... PSC.1-2012. The company’s work in countries throughout Southwest Asia, South America, and the ... degraded. The PSC.1 standard was created to protect fundamental freedoms and human rights ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... services, announced today that Claritas Capital, a Nashville-based private equity firm, has invested ... our expansion plans for some time, and Claritas Capital offers the smart money, ...
(Date:6/20/2017)... ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud to ... on Wednesday, June 21. , “Introducing our product on QVC is something we all worked ... our travel pillow to more than 90 million homes in the United States,” said FaceCradle ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Fresenius Vascular Care, ... minimally invasive techniques to treat and manage a wide range of vascular conditions, has ... initiative. With more than 65 centers represented by more than 40 local brands, a ...
(Date:6/20/2017)... ... June 20, 2017 , ... HOUSTON – Brazos Towers at Bayou Manor ... of new options for today’s modern senior. Brazos Towers at Bayou Manor has more ... love while offering them the services to support that lifestyle both now and in ...
Breaking Medicine News(10 mins):